Posted by Michael Wonder on 09 Feb 2021
FDA approves Libtayo (cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
9 February 2021 - Libtayo now approved for patients with advanced stages of the two most common skin cancers in the U.S.
The U.S. FDA has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) as the first immunotherapy indicated for patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.
Full approval was granted for patients with locally advanced basal cell carcinoma and accelerated approval was granted for patients with metastatic basal cell carcinoma.
